Loading...

CRISPR Therapeutics

DB:1CG
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1CG
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
1CG Share Price and Events
7 Day Returns
-8.2%
DB:1CG
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-31.6%
DB:1CG
-9.2%
DE Biotechs
-6.7%
DE Market
1CG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CRISPR Therapeutics (1CG) -8.2% -4.3% -2.5% -31.6% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 1CG underperformed the Biotechs industry which returned -9.2% over the past year.
  • 1CG underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
1CG
Industry
5yr Volatility vs Market

Value

 Is CRISPR Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CRISPR Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €31.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CRISPR Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CRISPR Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1CG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.44
NasdaqGM:CRSP Share Price ** NasdaqGM (2019-04-18) in USD $36.26
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CRISPR Therapeutics.

DB:1CG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CRSP Share Price ÷ EPS (both in USD)

= 36.26 ÷ -3.44

-10.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CRISPR Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CRISPR Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CRISPR Therapeutics's expected growth come at a high price?
Raw Data
DB:1CG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
-12.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CRISPR Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CRISPR Therapeutics's assets?
Raw Data
DB:1CG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.56
NasdaqGM:CRSP Share Price * NasdaqGM (2019-04-18) in USD $36.26
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:1CG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CRSP Share Price ÷ Book Value per Share (both in USD)

= 36.26 ÷ 7.56

4.79x

* Primary Listing of CRISPR Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CRISPR Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CRISPR Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CRISPR Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CRISPR Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CRISPR Therapeutics expected to grow at an attractive rate?
  • Unable to compare CRISPR Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CRISPR Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CRISPR Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1CG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1CG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts -12.6%
DB:1CG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 46.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1CG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1CG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 61 -142 -307 5
2022-12-31 14 -127 -292 5
2021-12-31 6 -111 -265 5
2020-12-31 10 -118 -224 8
2019-12-31 9 -127 -193 8
DB:1CG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -96 -165
2018-09-30 35 -83 -117
2018-06-30 37 -79 -91
2018-03-31 40 -69 -75
2017-12-31 41 -70 -68
2017-09-30 11 -75 -51
2017-06-30 10 -71 -41
2017-03-31 7 -69 -36
2016-12-31 5 -53 -23
2016-09-30 3 33 -53
2016-06-30 2 40 -44
2016-03-31 1 51 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CRISPR Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CRISPR Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1CG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from CRISPR Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1CG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -4.40 -3.27 -5.05 4.00
2022-12-31 -4.68 -3.25 -5.74 5.00
2021-12-31 -4.55 -3.24 -5.38 5.00
2020-12-31 -4.22 -3.02 -5.17 8.00
2019-12-31 -3.75 -3.17 -4.06 7.00
DB:1CG Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.44
2018-09-30 -2.60
2018-06-30 -2.11
2018-03-31 -1.81
2017-12-31 -1.71
2017-09-30 -1.35
2017-06-30 -1.41
2017-03-31 -1.74
2016-12-31 -1.89
2016-09-30 -9.64
2016-06-30 -8.02
2016-03-31 -5.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CRISPR Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess CRISPR Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CRISPR Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CRISPR Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CRISPR Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CRISPR Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CRISPR Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CRISPR Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CRISPR Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CRISPR Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1CG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.12 -164.98 48.29
2018-09-30 35.33 -117.25 43.08
2018-06-30 37.16 -91.25 41.01
2018-03-31 39.65 -75.18 36.04
2017-12-31 41.00 -68.36 35.85
2017-09-30 11.02 -51.40 34.60
2017-06-30 10.18 -41.37 30.60
2017-03-31 7.39 -36.21 31.58
2016-12-31 5.16 -23.18 31.06
2016-09-30 3.07 -52.55 25.21
2016-06-30 1.52 -44.22 23.56
2016-03-31 0.72 -30.71 16.95
2015-12-31 0.25 -25.50 13.40
2014-12-31 -7.01 5.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CRISPR Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CRISPR Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CRISPR Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CRISPR Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CRISPR Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CRISPR Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CRISPR Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CRISPR Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CRISPR Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CRISPR Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CRISPR Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CRISPR Therapeutics Company Filings, last reported 3 months ago.

DB:1CG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 392.20 0.00 456.65
2018-09-30 417.31 0.00 487.30
2018-06-30 265.15 0.00 319.74
2018-03-31 290.34 0.00 341.77
2017-12-31 187.83 0.00 239.76
2017-09-30 178.96 0.00 253.52
2017-06-30 197.80 0.00 272.26
2017-03-31 215.18 0.00 288.87
2016-12-31 232.85 0.00 315.52
2016-09-30 123.03 0.00 228.61
2016-06-30 135.34 0.00 246.85
2016-03-31 89.90 0.00 200.60
2015-12-31 35.40 38.34 155.96
2014-12-31 -0.70 0.00 0.95
  • CRISPR Therapeutics has no debt.
  • CRISPR Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CRISPR Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • CRISPR Therapeutics has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 91.6% each year.
X
Financial health checks
We assess CRISPR Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CRISPR Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CRISPR Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of CRISPR Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CRISPR Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CRISPR Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1CG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1CG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CRISPR Therapeutics has not reported any payouts.
  • Unable to verify if CRISPR Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CRISPR Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CRISPR Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of CRISPR Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess CRISPR Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CRISPR Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CRISPR Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CRISPR Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Samarth Kulkarni
COMPENSATION $6,934,265
AGE 39
CEO Bio

Dr. Samarth Kulkarni, Ph.D., has been the Chief Executive Officer of CRISPR Therapeutics AG since December 1, 2017 and served as its President since May 4, 2017 until December 1, 2017 and its Chief Business Officer since August 2015. He serves as Director of CRISPR Therapeutics AG. Dr. Kulkarni served as an Acting Principal Financial Officer of CRISPR Therapeutics AG since March 30, 2017 until November 2017 and served as its Principal Financial Officer since March 21, 2017. Dr. Kulkarni joined CRISPR Therapeutics from McKinsey and Company, where he was a Partner and had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in cutting edge areas such as personalized medicine and immunotherapy, where he co-authored several publications. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, which has been published in several leading journals. Dr. Kulkarni has a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology.

CEO Compensation
  • Samarth's compensation has increased whilst company is loss making.
  • Samarth's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CRISPR Therapeutics management team in years:

1.5
Average Tenure
51.5
Average Age
  • The average tenure for the CRISPR Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Rodger Novak

TITLE
Founder
COMPENSATION
$3M
AGE
51
TENURE
1.3 yrs

Samarth Kulkarni

TITLE
CEO & Director
COMPENSATION
$7M
AGE
39

Mike Tomsicek

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
52
TENURE
1.4 yrs

Tony Ho

TITLE
Head of R&D and Executive VP
COMPENSATION
$5M
TENURE
1.7 yrs

N. Coles

TITLE
Senior Advisor
COMPENSATION
$210K
AGE
58
TENURE
1.3 yrs

Emmanuelle Charpentier

TITLE
Co-Founder & Scientific Advisory Board Member

Chad Cowan

TITLE
Scientific Founder

Kala Subramanian

TITLE
Chief of Staff and Senior Vice President of Strategic Development & Operations
COMPENSATION
$2M
AGE
51
TENURE
2.8 yrs

Michael Esposito

TITLE
Acting Principal Accounting Officer
AGE
53
TENURE
2.1 yrs

Richard Schwartz

TITLE
Head of Technical Operations
Board of Directors Tenure

Average tenure and age of the CRISPR Therapeutics board of directors in years:

3.3
Average Tenure
51
Average Age
  • The tenure for the CRISPR Therapeutics board of directors is about average.
Board of Directors

Rodger Novak

TITLE
Founder
COMPENSATION
$3M
AGE
51
TENURE
1.3 yrs

Samarth Kulkarni

TITLE
CEO & Director
COMPENSATION
$7M
AGE
39

Emmanuelle Charpentier

TITLE
Co-Founder & Scientific Advisory Board Member

Tom Woiwode

TITLE
Independent Director
COMPENSATION
$177K
AGE
46
TENURE
5 yrs

Bill Lundberg

TITLE
Head of Scientific Advisory Board
COMPENSATION
$3M
AGE
55
TENURE
1.2 yrs

Kurt von Emster

TITLE
Independent Director
COMPENSATION
$182K
AGE
51
TENURE
4 yrs

Pablo Cagnoni

TITLE
Independent Director
COMPENSATION
$176K
AGE
55
TENURE
3.3 yrs

Craig Mello

TITLE
Member of Scientific Advisory Board

Matthew Porteus

TITLE
Member of Scientific Advisory Board

Dan Anderson

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Dec 18 Buy Vertex Pharmaceuticals Incorporated Company 26. Dec 18 27. Dec 18 40,198 €21.87 €878,423
26. Dec 18 Buy Vertex Pharmaceuticals Incorporated Company 21. Dec 18 24. Dec 18 90,742 €21.89 €1,915,336
18. Jan 19 Sell Abingworth LLP Company 17. Dec 18 18. Dec 18 -65,934 €29.18 €-1,732,296
17. May 18 Sell Versant Venture Management, LLC Company 15. May 18 15. May 18 -44,000 €49.50 €-2,150,354
16. May 18 Sell Abingworth LLP Company 11. May 18 14. May 18 -650,000 €47.54 €-29,536,977
X
Management checks
We assess CRISPR Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CRISPR Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Details
Name: CRISPR Therapeutics AG
1CG
Exchange: DB
Founded:
$1,697,862,526
52,635,645
Website: http://www.crisprtx.com
Address: CRISPR Therapeutics AG
Baarerstrasse 14,
Zug,
6300,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CRSP Common Shares Nasdaq Global Market US USD 19. Oct 2016
DB 1CG Common Shares Deutsche Boerse AG DE EUR 19. Oct 2016
LSE 0VRQ Common Shares London Stock Exchange GB USD 19. Oct 2016
Number of employees
Current staff
Staff numbers
188
CRISPR Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:29
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.